Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
subjects with prostate cancer, when administered as two injections twelve weeks apart.